Larvol Delta - Curis-Announces-Eleven-Active-Clinical-Sites-in-TakeAim-CLL-Study-Reaffirms-Patient-Dosing-Guidance-and-Reports-Stockholder-Approval-of-Reverse-Stock-Split

emavusertib (CA-4948) - Curis

https://www.prnewswire.com/news-releases/curis-announces-eleven-active-clinical-sites-in-takeaim-cll-study-reaffirms-patient-dosing-guidance-and-reports-stockholder-approval-of-reverse-stock-split-302811922.html

Jun 26, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next